Clinical Trial Update: A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update for CS1001 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• CS1001

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: COMPLETED